Drug Trial Radar · NCT02638337
Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause
Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
631
Actual
Start
Jan 26, 2016
Primary completion
Jun 23, 2017
Study completion Jul 5, 2017
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- First posted
- Dec 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.
Conditions
- Vaginal Dryness
Interventions
OspemifeneDrug
60 mg tablet
PlaceboDrug
Tablet identical to the ospemifene tablet without drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear at Week 12Time frame: Baseline and Week 12
- Change From Baseline in the Percentage of Superficial Cells in the Maturation Index of the Vaginal Smear at Week 12Time frame: Baseline and Week 12
- Change From Baseline in the Vaginal pH at Week 12Time frame: Baseline and Week 12
- Change From Baseline in the Severity of Self-reported Most Bothersome Symptom (MBS) of Vaginal Dryness at Week 12Time frame: Baseline and Week 12
- Number of Participants With Adverse EventsTime frame: From the first dose of study drug up to 14 days after the last dose; 14 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.